These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [Contribution of whole-body magnetic resonance in the diagnostics of monoclonal gammopathy of undetermined significance, multiple myeloma, and the assessment of Durie-Salmon Plus staging system]. Scudla V; Herman M; Minarík J; Pika T; Hrbek J; Bacovský J; Heinzová V Vnitr Lek; 2011 Jan; 57(1):52-60. PubMed ID: 21351663 [TBL] [Abstract][Full Text] [Related]
44. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias. Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491 [TBL] [Abstract][Full Text] [Related]
45. [A long-term observation of development from monoclonal gammopathy of undetermined significance (MGUS) into primary amyloidosis]. Kanoh T; Yago K; Okuma M Rinsho Ketsueki; 1990 Oct; 31(10):1740-4. PubMed ID: 2255066 [TBL] [Abstract][Full Text] [Related]
46. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells. Sezer O; Heider U; Zavrski I; Possinger K Haematologica; 2001 Aug; 86(8):837-43. PubMed ID: 11522540 [TBL] [Abstract][Full Text] [Related]
47. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Eisele L; Dürig J; Hüttmann A; Dührsen U; Assert R; Bokhof B; Erbel R; Mann K; Jöckel KH; Moebus S; Ann Hematol; 2012 Feb; 91(2):243-8. PubMed ID: 21789623 [TBL] [Abstract][Full Text] [Related]
48. Clinical aspects of multiple myeloma and related disorders including amyloidosis. Kyle RA Pathol Biol (Paris); 1999 Feb; 47(2):148-57. PubMed ID: 10192881 [TBL] [Abstract][Full Text] [Related]
49. [50-year-old man with fatigue and monoclonal gammopaty]. Raeder H; Kildahl-Andersen O; Stalsberg H Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2677-9. PubMed ID: 17972388 [TBL] [Abstract][Full Text] [Related]
50. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity. Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394 [TBL] [Abstract][Full Text] [Related]
51. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark. Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB; Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249 [TBL] [Abstract][Full Text] [Related]
52. Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades. Kyle RA; Therneau TM; Rajkumar SV; Larson DR; Plevak MF; Melton LJ Cancer; 2004 Dec; 101(11):2667-74. PubMed ID: 15481060 [TBL] [Abstract][Full Text] [Related]
53. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ]. Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009 [TBL] [Abstract][Full Text] [Related]
54. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management. Hillengass J; Moehler T; Hundemer M Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683 [TBL] [Abstract][Full Text] [Related]